The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,521.50
Bid: 1,521.00
Ask: 1,522.00
Change: 11.00 (0.73%)
Spread: 1.00 (0.066%)
Open: 1,511.50
High: 1,525.00
Low: 1,511.50
Prev. Close: 1,510.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Oct 2020 12:34

RNS Number : 9496C
GlaxoSmithKline PLC
22 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

GlaxoSmithKline PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City and country of registered office (if applicable)

Los Angeles, USA

4. Full name of shareholder(s)  (if different from 3)

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached:

20/10/2020

6. Date on which issuer notified (DD/MM/YYYY):

21/10/2020

7. Total positions of person(s) subject to the notification obligation:

 

% of voting rights attached to shares

(total of 8.A)

% of voting rights through financial instruments

(total of 8.B.1 + 8.B.2)

Total of both in %

(8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

4.9865%

0.00%

4.9865%

5,017,375,238

Position of previous notification (if applicable)

5.0803%

0.00%

5.0803%

 

       

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0009252882 Common Stock

 

204,695,637

 

4.0797%

US37733W1053 Depository Receipt

 

45,495,306

 

0.9068%

 

 

 

 

 

SUBTOTAL 8.A

250,190,943

4.9865%

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

N/A

 

 

 

 

 

 

SUBTOTAL 8.B.1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Physical or cash settlement

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

       

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

 

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Capital Research and Management Company

 

 

 

Capital Bank and Trust Company

 

 

 

Capital International Sàrl

 

 

 

Capital International, Inc.

 

 

 

Total

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional information:

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of four investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. CGII management companies and CB&T primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

 

Place of completion

Los Angeles

Date of completion

21/10/2020

 

 

        

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLMTBBTMTJTBBM
Date   Source Headline
13th May 20214:46 pmRNSDirector/PDMR Shareholding
11th May 202112:54 pmRNSDirector/PDMR Shareholding
11th May 202111:30 amRNSEMTN Prospectus
6th May 20215:50 pmRNSBoard and Committee Changes
5th May 20216:23 pmRNSResult of AGM
4th May 20214:29 pmRNSTotal Voting Rights
28th Apr 20215:33 pmRNSDirector/PDMR Shareholding
28th Apr 202112:00 pmRNS1st Quarter Results
26th Apr 20214:14 pmRNSDirector/PDMR Shareholding
23rd Apr 20213:00 pmRNSEU approves GSK’s JEMPERLI (dostarlimab-gxly)
23rd Apr 20217:00 amRNSFDA approves GSK’s JEMPERLI (dostarlimab-gxly)
16th Apr 20214:00 pmRNSDirector/PDMR Shareholding
15th Apr 20213:21 pmRNSDirector/PDMR Shareholding
15th Apr 202110:17 amRNSDirector/PDMR Shareholding
14th Apr 20212:14 pmRNSDirector/PDMR Shareholding
14th Apr 202111:58 amRNSDirector/PDMR Shareholding
12th Apr 20215:32 pmRNSDirector/PDMR Shareholding
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding
6th Apr 20212:30 pmRNSDirectorate Change
1st Apr 20213:36 pmRNSTotal Voting Rights
30th Mar 20214:21 pmRNSPublication of 2021 AGM Notice
30th Mar 202111:30 amRNSGSK respiratory product sales reporting changes
24th Mar 202112:30 pmRNSMoncef Slaoui Departs Galvani Bioelectronics
23rd Mar 20214:31 pmRNSDirector/PDMR Shareholding
17th Mar 20216:24 pmRNSChair of Audit & Risk Committee
16th Mar 202111:08 amRNSMedicago and GSK start Phase 3 trial
15th Mar 20215:27 pmRNSDirector/PDMR Shareholding
15th Mar 20217:00 amRNSAnnual Report 2020 on Form 20-F
11th Mar 20212:25 pmRNSDirector/PDMR Shareholding
11th Mar 20217:00 amRNSGSK and Vir share positive VIR-7831 data in COVID
10th Mar 20211:23 pmRNSDirector/PDMR Shareholding
9th Mar 20211:43 pmRNSAnnual Financial Report
2nd Mar 20213:48 pmRNSDirector/PDMR Shareholding
1st Mar 202110:55 amRNSTotal Voting Rights
25th Feb 202112:00 pmRNSGSK announces otilimab data for treatment of COVID
24th Feb 20211:59 pmRNSDirector/PDMR Shareholding
24th Feb 202112:13 pmRNSHolding(s) in Company
23rd Feb 20219:03 amRNSDirector/PDMR Shareholding
22nd Feb 20214:39 pmRNSDirector/PDMR Shareholding
22nd Feb 202110:40 amRNSSanofi and GSK initiate new Phase 2 study
19th Feb 202112:52 pmRNSDirector/PDMR Shareholding
19th Feb 202112:31 pmRNSDirector/PDMR Shareholding
19th Feb 202110:32 amRNSDirector/PDMR Shareholding
18th Feb 20219:59 amRNSDirector/PDMR Shareholding
17th Feb 202112:00 pmRNSGSK/Vir collaborate on antibodies for influenza
17th Feb 20219:00 amRNSDirector/PDMR Shareholding
15th Feb 202110:09 amRNSDirector/PDMR Shareholding
15th Feb 20219:15 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.